[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-340761-en":59,"doc-seo-340761-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},340761,1099514068365,"Aurelia","https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment","Gastrointestinal (GI) cancers remain prevalent globally, with limited survival improvements despite advances in surgery, radiotherapy, and chemotherapy. Cluster of differentiation 47 (CD47) is frequently overexpressed in GI cancers and is linked to poor prognosis, suggesting value as an early diagnostic marker. This review summarizes the structure and functions of CD47 and SIRPa, their roles in signaling pathways, CD47’s prognostic significance, current therapeutic strategies targeting the CD47-SIRPa axis in GI cancer, and key issues for future research.","Journal of Pharmaceutical Analysis 15 (2025) 101099  \nContents lists available at ScienceDirect  \nJournal of Pharmaceutical Analysis  \njournal [homepage:](homepage: www. elsevier. com/locate/jpa)[ www. elsevier. com/locate/jpa](homepage: www. elsevier. com/locate/jpa)  \n| Review paper\u003Cbr>Therapeutic strategies targeting CD47-SIRPa signaling pathway in gastrointestinal cancers treatment\u003Cbr>Zhengping Che a, Wei Wang b, ***, Lin Zhang c, **, Zhenghong Lin a, *\u003Cbr>a School of Life Sciences, Chongqing University, Chongqing, 401331, China\u003Cbr>b Department of Cancer Center, Chongqing University Three Gorges Hospital, School of Medicine, Chongqing University, Chongqing, 404000, China c Department of Gastroenterology, Chongqing University Jiangjin Hospital, Chongqing, 402260, China |  |  | |\n| --- | --- | --- | --- |\n| a r t i c l e i n f o |  | a b s t r a c t |  |\n| Article history:\u003Cbr>Received 28 March 2024\u003Cbr>Received in revised form\u003Cbr>4 September 2024\u003Cbr>Accepted 7 September 2024\u003Cbr>Available online 12 September 2024 |  | Gastrointestinal (GI) cancers are prevalent globally, with leading incidence and mortality rates among malignant tumors. Despite notable advancements in surgical resection, radiotherapy, and chemotherapy, the overall survival rates remain low. Hence, it is imperative to explore alternative approaches that enhance patient outcomes. Cluster of differentiation 47 (CD47), serving as an early diagnostic marker, is predominantly overexpressed in GI cancers and associated with poor prognosis. Targeting the CD47-signal regulatory protein alpha (SIRPa) signaling pathway may provide a novel strategy for GI cancers treatment. This study summarizes current knowledge of the structure and function of CD47 and SIRPa, their roles in signaling pathways, the prognostic signiﬁcance of CD47, therapeutic strategies targeting the CD47-SIRPa signaling pathway in GI cancer, and highlights key issues for future investigations.\u003Cbr>© 2024 The Author(s). Published by Elsevier B.V. on behalf of Xi’an Jiaotong University. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)). |  |\n| Keywords:\u003Cbr>CD47-SIRPa\u003Cbr>Signaling pathway\u003Cbr>Immune checkpoint blockade Immunotherapy\u003Cbr>GI cancers |  |  |  |\n\n1. Introduction  \nGastrointestinal (GI) cancers, including esophageal, gastric, colorectal, pancreatic, and hepatocellular carcinoma (HCC), are prevalent worldwide, with the highest incidence and mortality rates [1]. Various treatment options, such as surgical resection, radiotherapy, and chemotherapy, have improved patient outcomes [2]. However, the prognosis for some GI cancers remains poor. Consequently, there is a critical need for innovative strategies to address GI cancers. Checkpoint inhibitor immunotherapy is a rapidly advancing ﬁeld, showing promise in treating GI cancers.  \nThe homeostatic balance of the immune system is crucial in the development of GI cancers. Research on immunotherapy targeting immune checkpoint blockade has made signiﬁcant breakthroughs [3]. The development of immune checkpoint inhibitors (ICIs), such as programmed cell death protein-1 (PD-1) and programmed cell death-ligand 1 (PD-L1), as well as cytotoxic T lymphocyteassociated antigen 4 (CTLA-4), has enhanced the prognosis for patients [4]. However, a proportion of patients still progress to distant  \n* Corresponding author.  \n** Corresponding author.  \n*** Corresponding author.  \n[E-mail addresses:](E-mail addresses: wangwei929@cqu.edu.cn)[ wangwei929@cqu.edu.cn](E-mail addresses: wangwei929@cqu.edu.cn) (W. Wang), [brucezhanglin@cqu.edu](brucezhanglin@cqu.edu). cn (L. Zhang), [zhenghonglin@cqu.edu.cdu.cn](zhenghonglin@cqu.edu.cdu.cn) (Z. Lin).  \nmetastasis and treatment resistance, with an overall low response rate [5]. New immune checkpoint treatment strategies are therefore urgently needed to improve the prognosis of GI cancers [6]. One potential target is","cbCairYu58VNrvai","https://ap.wps.com/l/cbCairYu58VNrvai","pdf",2405172,17,"English","en",105,"# Introduction\n# CD47-SIRPa signaling pathway in GI cancers\n# Therapeutic strategies targeting CD47-SIRPa signaling\n# Future perspectives and key issues","[{\"question\":\"Why is targeting the CD47-SIRPα signaling pathway relevant for GI cancers?\",\"answer\":\"CD47 is overexpressed in GI cancers and is associated with poor prognosis. The CD47–SIRPα interaction helps cancer cells evade immune surveillance by suppressing phagocytosis, so blocking this axis may enhance anti-tumor innate immunity.\"},{\"question\":\"What are the main roles of the CD47–TSP1 interaction described in the review?\",\"answer\":\"CD47 binding to TSP1 downregulates immune responses by inhibiting inflammatory response and immune cell phagocytosis. It also participates in processes such as angiogenesis, tumor growth, and metastasis.\"},{\"question\":\"How does the CD47–SIRPα interaction affect macrophage and dendritic cell activity?\",\"answer\":\"The interaction inhibits the phagocytosis functions of macrophages and dendritic cells, thereby reducing inflammatory responses and immune cell activation. This supports immune evasion and contributes to reduced regulation of innate and adaptive immunity.\"}]","Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment | PDF",1790038761,43,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05d4f2f51cbaaaf6193f5fad207b7fb7.webp",983,1310,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f519814cf42c22b6302bd06fa9a21f7.webp",982,1309,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96902f5ed092923d1613271d405574b1.webp",981,1308,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c53c1b61a9872e6beef96179cd5f59c8.webp",980,1306,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"therapeutic-strategies-targeting-cd47-sirp-signaling-pathway-in-gastrointestinal-cancers-treatment","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/therapeutic-strategies-targeting-cd47-sirp-signaling-pathway-in-gastrointestinal-cancers-treatment/340761/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/therapeutic-strategies-targeting-cd47-sirp-signaling-pathway-in-gastrointestinal-cancers-treatment/340761.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":136,"interactionType":137,"userInteractionCount":52},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"Why is targeting the CD47-SIRPα signaling pathway relevant for GI cancers?","Question",{"text":146,"@type":147},"CD47 is overexpressed in GI cancers and is associated with poor prognosis. The CD47–SIRPα interaction helps cancer cells evade immune surveillance by suppressing phagocytosis, so blocking this axis may enhance anti-tumor innate immunity.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"What are the main roles of the CD47–TSP1 interaction described in the review?",{"text":151,"@type":147},"CD47 binding to TSP1 downregulates immune responses by inhibiting inflammatory response and immune cell phagocytosis. It also participates in processes such as angiogenesis, tumor growth, and metastasis.",{"name":153,"@type":144,"acceptedAnswer":154},"How does the CD47–SIRPα interaction affect macrophage and dendritic cell activity?",{"text":155,"@type":147},"The interaction inhibits the phagocytosis functions of macrophages and dendritic cells, thereby reducing inflammatory responses and immune cell activation. This supports immune evasion and contributes to reduced regulation of innate and adaptive immunity.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1790167866]